Fed. Circ. Sides With GSK, Others In Argatroban IP Row

Law360, New York (August 2, 2011, 4:30 PM EDT) -- The Federal Circuit upheld a win Tuesday for GlaxoSmithKline PLC, Mitsubishi Chemical Corp. and Encysive Pharmaceuticals Inc. in a patent battle with Barr Laboratories Inc. over anti-coagulant drug Argatroban, affirming a decision that Barr's invalidity claims didn't hold water.

A three-judge panel denied defendant-appellant Barr's challenge to a lower court's judgment that the Mitsubishi patent-in-suit was valid.

Mitsubishi and the other plaintiffs slapped Barr with the suit after the company sought approval for a generic version of injectable Argatroban, and Barr argued that the four patent...
To view the full article, register now.